## IN THE CLAIMS

Amend the claims as indicated below by the markings. Cancel claims 9, 18, 19, 20, and 40 - 48 without prejudice.

Claims 1 - 4. (Cancelled)

5. (Currently Amended) The transgenic mutant mouse according to claim 33 [[1]], wherein the genome of the transgenic mutant mouse comprises a transgene within the disrupted region introduced in the endogenous Sigma-1 receptor gene that comprises a sequence encoding a positive selection marker.

Claims 6 -16. (Cancelled)

 (Currently Amended) An isolated cell from a transgenic mouse, deficient in an endogenous Sigma-I receptor, according to claim 33 [[1]], or its offspring.

Claims 18 - 27. (Cancelled)

28. (Currently Amended) The cell according to claim 17 [[19]] wherein the cell is immortalized

Claims 29 - 32. (Cancelled)

33.(Currently Amended) A transgenic mutant mouse , comprising a mouse whose genome comprises includes a mutation that disrupts the having a disruption in a gene of an endogenous Sigma-1 receptor, and the transgenic mutant mouse when said gene-disruption giving rise to a fertile homozygous for said mutation lacks transgenic mutant mouse lacking detectable levels of endogenous Sigma-1 receptor and has , said transgenic mutant mouse having a phenotype characterized by a statistical difference in hyperactivity response compared to wild-type control wild mice.

34. (Currently Amended) A transgenic mutant mouse as claimed in claim 33, wherein said <u>transgenic</u> mutant mouse is obtainable by the use of the vector identified as pHR53TK that is deposited in the CECT under access number CECT 5737, to insert a functional disruption in the endogenous Sigma-1 receptor.

Claim 35.and 36. (Cancelled)

37.(Currently Amended) A transgenic mutant mouse wherein said transgenic mutant mouse is an offspring of a transgenic mutant mouse according to claim 33 and is homozygous for the mutation in the endogenous Sigma-1 receptor.

38.(Previously Presented) A transgenic mutant mouse as claimed in claim 33, wherein the genome of the transgenic mutant mouse comprises a transgene within the mutation introduced in the endogenous Sigma-1 receptor gene that comprises a gene encoding a positive or negative selection marker.

39.(Previously Presented) A transgenic mutant mouse as claimed in claim 38, wherein said transgene comprises the neomycin phototransferase (neo) gene.

Claims 40.- 48 (Cancelled)